Aschenbrenner Andrew J, Petros Jennifer, McDade Eric, Wang Guoqiao, Balota David A, Benzinger Tammie Ls, Cruchaga Carlos, Goate Alison, Xiong Chengjie, Perrin Richard, Fagan Anne M, Graff-Radford Neill, Ghetti Bernardino, Levin Johannes, Weidinger Endy, Schofield Peter, Gräber Susanne, Lee Jae-Hong, Chhatwal Jasmeer P, Morris John C, Bateman Randall, Hassenstab Jason
Charles F. and Joanne Knight Alzheimer Disease Research Center Department of Neurology Washington University School of Medicine St. Louis Missouri USA.
Division of Biostatistics Washington University School of Medicine St. Louis Missouri USA.
Alzheimers Dement (Amst). 2020 Jun 23;12(1):e12038. doi: 10.1002/dad2.12038. eCollection 2020.
Changes in personality characteristics are associated with the onset of symptoms in Alzheimer's disease (AD) and may even precede clinical diagnosis. However, personality changes caused by disease progression can be difficult to separate from changes that occur with normal aging. The Dominantly Inherited Alzheimer Network (DIAN) provides a unique cohort in which to relate measures of personality traits to in vivo markers of disease in a much younger sample than in typical late onset AD.
Personality traits measured with the International Personality Item Pool at baseline from DIAN participants were analyzed as a function of estimated years to onset of clinical symptoms and well-established AD biomarkers.
Both neuroticism and conscientiousness were correlated with years to symptom onset and markers of tau pathology in the cerebrospinal fluid. Self-reported conscientiousness and both neuroticism and conscientiousness ratings from a collateral source were correlated with longitudinal rates of cognitive decline such that participants who were rated as higher on neuroticism and lower on conscientiousness exhibited accelerated rates of cognitive decline.
Personality traits are correlated with the accumulation of AD pathology and time to symptom onset, suggesting that AD progression can influence an individual's personality characteristics. Together these findings suggest that measuring neuroticism and conscientiousness may hold utility in tracking disease progression in AD.
人格特征的变化与阿尔茨海默病(AD)症状的出现相关,甚至可能先于临床诊断。然而,疾病进展引起的人格变化可能难以与正常衰老过程中发生的变化区分开来。显性遗传阿尔茨海默病网络(DIAN)提供了一个独特的队列,在这个队列中,可以将人格特质测量与疾病的体内标志物联系起来,该队列的样本比典型的晚发性AD患者年轻得多。
分析DIAN参与者在基线时用国际人格项目池测量的人格特质,将其作为估计的临床症状出现年限和成熟的AD生物标志物的函数。
神经质和尽责性都与症状出现的年限以及脑脊液中tau病理学标志物相关。自我报告的尽责性以及来自旁证来源的神经质和尽责性评分都与认知衰退的纵向速率相关,即被评为神经质较高且尽责性较低的参与者表现出加速的认知衰退速率。
人格特质与AD病理学的积累和症状出现的时间相关,这表明AD进展可以影响个体的人格特征。这些发现共同表明,测量神经质和尽责性可能在跟踪AD疾病进展方面具有实用价值。